Gb0139 galecto
Web1 day ago · Galecto has multiple ongoing Phase 2 clinical programs in fibrosis and cancer, including (i) an inhaled galectin-3 modulator (GB0139) in a Phase 2b trial for the treatment of idiopathic pulmonary ... Webcenters globally, investigating the safety and efficacy of Galecto s lead compound, GB0139, in patients with IPF. Initial unblinded data readout is anticipated in 2024. The DSMB informed the company, based on unblinded safety and efficacy data, that there was an imbalance in the serious adverse experiences
Gb0139 galecto
Did you know?
WebGalecto Biotech is a biotechnology company that develops small molecules for the treatment of severe diseases, including fibrosis, cancer and inflammation. The company was founded in 2011 by leading galectin scientists and biotech executives from Sweden, United Kingdom, and Denmark. ... Galecto’s lead product candidate, GB0139, is an inhaled ... WebFeb 6, 2024 · Prior use of GB0139 (also called TD139) or previously randomized in GALACTIC-1. ... Galecto Biotech AB: ClinicalTrials.gov Identifier: NCT03832946 Other …
WebGalecto develops small molecules for the treatment of severe diseases, including fibrosis and cancer. The company lead product candidate, GB0139, is an inhaled inhibitor of galectin-3. GB0139 is being developed for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, in which there is high unmet medical WebDrug DetailsGB0139 (formerly TD139) is a galectin-3 inhibitor administered by dry powder inhalation.Study PurposeThis is a randomized, double-blind, placebo-controlled phase …
WebGalecto was founded by leading fibrosis-focused scientists and biotech executives and is built on more than 10 years of research into galectin and fibrosis modulators. Our team … Web1 day ago · Galecto has multiple ongoing Phase 2 clinical programs in fibrosis and cancer, including (i) an inhaled galectin-3 modulator (GB0139) in a Phase 2b trial for the …
WebJan 1, 2024 · TD139 (GB0139) Galecto, Inc. (Copenhagen, Denmark) Dry powder inhaler QD • Phase Ia/Ib - safety, tolerability, PK and biomarkers in healthy volunteers and patients with IPF completed (NCT02257177). • Phase IIb - efficacy and safety study (GALACTIC-1, NCT03832946) in IPF patients. GB1211: Galecto, Inc. (Copenhagen, Denmark) Oral …
WebApr 13, 2024 · Galecto has multiple ongoing Phase 2 clinical programs in fibrosis and cancer, including (i) an inhaled galectin-3 modulator (GB0139) in a Phase 2b trial for the treatment of idiopathic pulmonary fibrosis; (ii) an orally active LOXL2 inhibitor (GB2064) in a Phase 2a trial for the treatment of myelofibrosis; (iii) an orally active galectin-3 ... high quality cpdWebApr 14, 2024 · On Wednesday, April 12th, Orbimed Advisors Llc sold 2,363 shares of Galecto stock. The stock was sold at an average price of $1.81, for a total value of … how many cabinet ministers help doug fordWebJan 10, 2024 · Galecto was founded in 2011 with Lund University academic galectin research leaders Ulf Nilsson and Hakon Leffler, and has had a research focus on galectin-3 modulators to treat fibrotic diseases. We recently covered another Galecto development compound, GB1211, a related oral galectin-3 inhibitor, Ph. how many cabinet ministers in uk governmentWebThe anti-fibrotic effect of GB0139, a small molecule galectin-3 inhibitor, in precision cut lung slices from IPF tissue (ICLAF 2024) - "The reduction in Gal-3 levels was associated with a reduction in markers of fibrosis comparable to that observed with pirfenidone and nintedanib. In IPF PCLuS, GB0139 demonstrates Gal-3 target engagement that ... high quality cowboys diaper bagWebApr 26, 2024 · The study is designed to investigate the safety and efficacy of Galecto’s most advanced compound, GB0139, in 141 patients with IPF. Patients in GALACTIC-1 … how many cabinet positions are there todayWebMay 22, 2024 · On May 6, Galecto announced that it had recruited more than 150 patients to date for its Phase IIb GALACTIC-1 study of GB0139 (formerly TD139) for idiopathic pulmonary fibrosis (IPF). GP0139 is an inhaled galectin-3 inhibitor. The company stated that its ability to recruit, especially in areas that have been most affected by Covid-19, namely ... how many cabinet offices are thereWebApr 13, 2024 · Galecto has multiple ongoing Phase 2 clinical programs in fibrosis and cancer, including (i) an inhaled galectin-3 modulator (GB0139) in a Phase 2b trial for the … high quality cpr children